Bayer AG (BAYRY)

BAYRY Pharma/Crop Science

BiotechSign Signal Grade

C
Signal Grade
55.9/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Dilution Risk
40
Clinical Activity
100
Short Interest
10

Pipeline Overview

Therapeutic Focus
Pharma/Crop Sciencesrc

Clinical Trial Activity

156
Clinical Trials
(ClinicalTrials.gov aggregate)
23 Phase 1, 45 Phase 2, 29 Phase 3, 8 Phase 4
Trial Phase Breakdown
0
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Dilution Risk

MEDIUM DILUTION RISK
40/100
Dilution Score
40Warrant Risk
40Convertible Risk
40Offering Ability

Dilution score: 40/100 (MEDIUM), cash runway not available

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

0.00%
Float Shorted
1.0
Days to Cover
LOW
Squeeze Risk
+15.1%
SI Change
INCREASING
Trend
415,421
Shares Short

Short interest: ?% of float, squeeze risk: LOW

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Bayer AG.

Full BAYRY Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.